That $10-15M is the revenue range in which they project to be profitable, not the range of expected revenues. That's my impression. Read the transcript...plain as day. What did you expect the revenue growth to be from Q416? I don't remember Damaj ever giving a quarterly projection. If they maintain the same quarterly growth, they're on pace to meet $15M, even without Fluticare....exactly what Damaj said, right? Just because Honey said it should be $2.65M doesn't mean that was ever in the cards...let's be honest. You've gotta like what they're doing to manage cost too. Clearly they're not burning through cash, and marketing/SG&A is decreasing significantly in proportion to revenue generated...clearly a function of the distribution channels they've developed. And I think they low-balled the revenues for Fluticare ramp....1-1.5% market penetration seems like a very low estimate for penetrating a $1B market where they have the highest prescription brand equity....even if that's to be anticipated due to a slower marketing/distribution ramp, that's still all icing on the cake for 2017 because they're on the trajectory for $15M regardless.
